Long-term calorie restriction protects rat pituitary growth hormone-releasing hormone binding sites from age-related alterations.
In mammals, middle age and late adulthood is characterized by a decrease of growth hormone (GH) secretion and insulin-like growth factor 1 (IGF-1) serum levels, contributing to tissue and organ atrophy. This condition is related, at least in part, to alterations of pituitary GH-releasing hormone (GHRH) receptor-binding sites. Prevention of age-related deterioration of tissues and organs, retardation of the onset or progression of a wide range of age-related diseases and extension of both mean and maximum life span can be achieved through life-long moderate calorie restriction (CR). Because CR has been reported to positively modulate the somatotropic axis resulting in the maintenance of a youthful GH secretory pattern in aged rats, we investigated whether or not benefits of a long-term (10 months) 40% CR, started in 8-month-old male Sprague-Dawley rats, was accomplished by preventing age-related alterations of pituitary GHRH receptor binding sites. We also studied whether or not a short-term (50 days) 40% CR, started in 16-month-old rats, could revert them. Potential hormonal and metabolic modulators of the GHRH receptors were investigated as well. GHRH binding parameters were derived from saturation studies performed in pituitary homogenates with [125I-Tyr10]hGHRH (1-44)NH2. As previously reported, the high affinity GHRH receptor-binding sites were blunted in 18-month-old ad libitum-fed rats and the apparent concentration of total binding sites was reduced. Short-term CR neither restored high affinity GHRH binding sites nor increased the apparent concentration of total binding sites. On the contrary, long-term calorie-restricted 18-month-old rats exhibited high and low affinity GHRH binding sites (Kd1: 1.73 +/- 0.35 nM; Kd2: 310 +/- 41 nM; Bmax1: 183 +/- 55 fmol/mg protein; Bmax2: 30 +/- 3 pmol/mg protein) as found in 2-month-old rats (Kd1: 0.68 +/- 0.15 nM; Kd2: 350 +/- 47 nM; Bmax1: 219 +/- 53 fmol/mg protein; Bmax2: 84 +/- 9 pmol/mg protein). Our results imply that CR must be implemented before age-related alterations of GHRH receptor-binding sites become too severe or that CR has to be carried out for a long period of time, independently from the age at which it begins. Protection of pituitary GHRH binding sites from age-related alterations could not be attributed to changes in circulating levels of total or free T4 or free fatty acids. Finally, the anti-aging effect of a long-term CR observed at the level of pituitary GHRH receptors does not result in a significant increase of total IGF-1 circulating levels. Identification of molecular and cellular mechanisms responsible for these actions will deserve attention in order to identify centrally and/or peripherally active classes of molecules that could preserve, in aging mammals, the functionality of the somatotropic axis through selective regulation of pituitary GHRH receptors.
Neuroendocrinology Laboratory, Louis-Charles Simard Research Center, Notre-Dame Hospital, Montreal, Quebec, Canada.
N
N
Girard
G
G
Ferland
L
L
Boulanger
P
P
Gaudreau
D000375:Aging / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D001835:Body Weight; D002149:Energy Intake; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005269:Femur / Q000033:anatomy & histology; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D010902:Pituitary Gland / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013974:Thyroxine / Q000097:blood; D013977:Tibia / Q000033:anatomy & histology
D005230:Fatty Acids, Nonesterified; D007334:Insulin-Like Growth Factor I; D013007:Growth Hormone-Releasing Hormone; D013974:Thyroxine